We have assembled a world-class management and scientific team of industry Research and Development leaders from Roche, Pfizer, Merck, BMS, Lilly, AstraZeneca and the U.S. FDA as well as, those from Academia. The Innovimmune team has a successful Discovery, Development and Commercialization track-record of advancing >100 NMEs across all drug development lifecycles, >100 worldwide patent filings and >300 peer-reviewed scientific publications (including Science and Nature) mostly within the Autoimmune, Immuno-Inflammation & Oncology therapeutic areas.

Xeljanz®, Zelboraf®, Cyramza®, Xeloda®, Xermelo®, Selzentry®, Fuzeon®, Victrelis®, Tamiflu®, Pegasys®, Copegus®, Sarasar®, Vfend®, Viagra®, Farxiga®, Nexium®, Crestor®, Tykosyn®, Prograf®, CellCept®, Zenapax®, GPCRs, NHRs, RNAi, kinases, PI3K, mTOR, CDK2, MMP-13, TACE, 5-HT6, S1P1/5, CD20, CD25/IL-2R, IL-4, IL-10, IL-15, a4b7-integrin, PAF, glucokinase, 11b-HSD, CRTH2 receptor, CB2, caspase-2/-8, MR antag, CCR1, ERK, p38, ZAP70, SGLT2, inhaled GR and peripheral kappa agonists.

Our experienced Discovery and Development experts from the pharmaceutical and biotechnology industries represent the best of their individual fields in Translational Medicine, Clinical Development, Computational Chemistry, Medicinal Chemistry, Biochemistry, Biophysics, Enzymology, Drug Metabolism & Pharmacokinetics, Molecular Biology, Cell Biology, Immunology, Pharmacology, Pathology and Biochemistry. We are industry experts in the fields of Autoimmunity, Inflammation, Cytokine, Chemokine, Nuclear Hormone Receptors, GPCRs, Signal Transduction and Kinase Biology with the unique credentials to innovate the drug discovery and exploratory development of novel NME targets for Autoimmune & Immuno-Inflammatory Diseases and Cancer.